Please assess the completion status of the following clinical trial:

Trial Title: Post-stroke Neural Plasticity With Atomoxetine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic stroke patients~* Single stroke~* Chronic (more than 6 months after from stroke)~* At least 21 years old, but there is no upper age range for this project.~* Participants NOT able to extend the affected metacarpophalangeal joints at least 10° and the wrist 20°.~Exclusion Criteria:~* History of head injury with loss of consciousness~* History of severe alcohol or drug abuse~* History of psychiatric illness~* Unstable cardiac dysrhythmia~* High blood pressure (systolic pressure \>160 mm Hg and/or diastolic pressure \>100 mm Hg)~* History of myocardial infarction or unstable angina~* Pregnancy~* Glaucoma, history of hypersensitivity or idiosyncrasy to sympathomimetic drugs.~* Subjects using drugs suspected of interfering with plasticity, such as MAOI, alpha-adrenergic antagonists, benzodiazepines, muscarinic receptor antagonists, dopaminergic antagonists, or other neuroleptics within 3 months of recruitment.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Atomoxetine with motor training (Type: EXPERIMENTAL): 40 mg atomoxetine paired with task-oriented therapy for 10 consecutive weekdays
- Placebo with motor training (Type: PLACEBO_COMPARATOR): Placebo capsules paired with task-oriented therapy for 10 consecutive weekdays

Based on this trial design, predict the completion outcome and termination type (if applicable).